pmlive
Amidst the massive technological and social changes upending the societal status quo, the culture of doctors around the globe is also in flux according to The Truth About Doctors, a new global research study conducted by McCann Health, in partnership with McCann Truth Central. This landmark study which surveyed nearly 2,000 doctors in 16 markets, found that the practice of medicine is not everything doctors thought it would be. In fact, the expectations of the job are startling mismatched to the realities of the high-volume, cost-cutting, technology-driven health environment we live in today. There is a massive gap between expectations and reality for doctors around the globe that is impacting their ability to do their job, as well as their enthusiasm for it.
Watch Now
pharmtech
Formulators modify the release profiles of drugs for multiple reasons: to target delivery of the API, enhance bioavailability, provide dosage convenience, improve patient adherence, and extend the patentable life cycle of an existing drug.Whether the desired profile is for immediate or modified release, formulators must overcome the development hurdles of poorly soluble APIs. Modified-release drugs may require more excipients and more complex formulations and manufacturing steps, resulting in longer, and more expensive, development processes. Proven formulation methods and careful excipient selection, however, can be employed to develop formulations for modified release drugs that offer value to the patient.
Watch Now
The aim of this webinar is to promote the fight against IP Crime in the area of Counterfeiting and Pharmaceutical Products.
Watch Now
Advanced Cell Diagnostics Inc.
Intratumor heterogeneity (ITH) is a major underlying cause of therapy resistance and disease recurrence and is a read-out of how a tumor has grown. Current methods to analyze genetic ITH rely on the sequencing of ‘bulk’ or flow-sorted populations, in which the spatial context of tumor subclones is not preserved, and rare subclones may not be detected. These shortfalls can be addressed with BaseScope™ ISH–a unique mutation-specific RNA in situ hybridization assay. The BaseScope assay represents a significant technical advance for in situ mutation detection and provides new insight into the mechanisms of tumor evolution with potential ramifications for selecting patients for treatment. Join us to learn more about this new approach to ITH analysis.
Watch Now